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Non-invasive assessment of endothelial 
function — a review of available methods
ABSTRACT
The key role of the endothelium in vascular-dependent diseases led to an increase in scientific interest in 
examining the endothelial function as a tool for screening, as well as for monitoring of the disease and its 
treatment. In the period from 2016 till 2019, a high level of scientific interest in the assessment of endothelial 
function has been observed, as expressed in the number of published clinical trials between 369 and 477 
per year with the total number of subjects between 49,634 and 75,934.
Currently, none of the known methods of assessing vascular endothelial function is widely used in clinical 
practice. This may be a result of various factors: scientific (lack of standardization in terms of quantitative 
indicators of endothelial function), formal (lack of official recommendations for endothelial assessment), 
financial (the best-validated methods and devices are costly, which renders it unsustainable to use them 
in screening diagnostics) and technological (high susceptibility of many measurement methods to errors). 
Nevertheless, it can be expected that non-invasive methods for the early detection of endothelial dysfunction 
in screening programs will gradually gain importance.
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Introduction
Endothelial dysfunction precedes the appearance of 
atherosclerotic lesions and their clinical symptoms. Ear-
ly pathology detection allows the implementation of 
adequate preventive treatment [1–6]. The study aimed 
to review non-invasive methods of endothelial function 
assessment as an attractive option for early diagnosis 
and an interesting research area. 
Endothelial function assessment 
— general assumptions 
The vast majority of non-invasive methods for endo-
thelial function assessment are based on the phenome-
non of reactive hyperaemia. The flow-mediated dilation 
(FMD) method is based on the ability of endothelium 
cells to regulate peripheral resistance, while endothelial 
dysfunction is defined as the impairment of vasodilation 
due to the secretion of endothelium-derived relaxing 
factor EDRF [7–10]. The identification of EDRF as nitric 
oxide (NO) was awarded the Nobel Prize in 1998 [11, 12]. 
Among the factors modulating the vascular endo-
thelium function, shear stress is the most convenient to 
apply in clinical practice. The sudden change of shear 
stress leads to the reactive hyperaemia commonly 
used in non-invasive tests of the endothelium. The 
post-occlusion reactive hyperaemia (PORH) is defined 
as an increase in blood flow following the artery occlu-
sion due to EDRF release [13, 14]. While not all details 
of the mechanism of reactive hyperaemia have been 
established so far, a general pattern can be drawn in 
the form of a cause-and-effect sequence following the 
artery occlusion (i.e., deflation of the occlusive cuff). The 
decrease in peripheral resistance due to vasodilation of 
the arterioles causes an analogous blood flow increase 
in the conduit arteries. An increase in blood flow causes 
a proportional increase in shear forces, and this directly 
induces endothelial cell mechanoreception pathways re-
sulting in the increased secretion of nitric oxide, which, in 
turn, causes vasodilation of the conduit arteries [15, 16].
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Application of endothelial function 
assessment in clinical studies
The key role of the endothelium in vascular-de-
pendent diseases has led to an increase in scientific 
interest in examining the endothelial function as a tool 
for screening, as well as for monitoring of the disease 
and its treatment [13–16]. Apart from the already ex-
isting atherosclerosis, the functioning of the vascular 
endothelium is influenced by, among others:
 — Arterial hypertension,
 — Hyperlipidaemia,
 — Diabetes mellitus,
 — Hyperhomocysteinaemia,
 — Heart failure,
 — Tobacco smoking,
 — Age,
 — Inflammatory factors,
 — Menopause [1, 2, 17]. 
Recently, a considerable number of studies apply-
ing endothelial function assessment as a research tool 
have been published. The authors conducted a search 
covering the period from 1st January 2016 to 31st De-
cember 2020 using the MEDLINE database with “endo-
thelial function” as the only keyword. The initial search 
revealed 61,399 records. Only 1,873 of those articles, 
classified as clinical trials, were included for further 
analysis. References of those studies were searched 
manually for studies in which endothelial function was 
assessed. The final analysis comprised 1,742 studies in 
which several subjects who underwent endothelial func-
tion assessment was reported. For each eligible study, 
the number of studied subjects was defined (Tab. 1). 
In the period from 2016 till 2019, a high level of sci-
entific interest in the assessment of endothelial function 
has been observed, as expressed in the number of 
published clinical trials between 369 and 477 per year 
with the total number of subjects between 49,634 and 
75,934. The sudden decline in the number of published 
studies and the total number of participants seen in 
2020 is likely an effect of the COVID-19 pandemic. 
Therefore, a further increase in the number of such 
studies should be assumed once the restrictions are 
eased. It should be emphasized that the performed 
analysis was limited using only one keyword in one 
of the most prestigious databases, which groups only 
the best scientific journals and the yet impressive total 
number of 262,218 people who underwent assessment 
of endothelial function was reported. Thus, the actual 
number of endothelial function tests carried out in the 
analysed period might have been much higher. 
Methods of endothelial function 
assessment 
Understanding the importance, and thus the growing 
interest in endothelial pathophysiology has led to the de-
velopment of several methods for invasive or non-invasive, 
quantitative evaluation of its function [1–4]. Most of these 
methods are based on the assumptions: that firstly certain 
types of stimulation trigger the nitric oxide production 
leading to local vasodilation, and secondly endothelial 
dysfunction is a systemic disorder, therefore can be tested 
in any arterial vessels, most often on easily accessible 
arteries of the upper limbs [18]. To determine the severity 
of the endothelial reaction the baseline (reference level) of 
the assessed parameter should be defined as a reference 
to its value after the stimulation. Some methods need to 
employ additional mathematical methods to compensate 
for the effects of extra-endothelial factors that may interfere 
with the measurement of the local response [19].
In-vitro methods 
The in-vitro methods of endothelial function assess-
ment are based on the analysis of the concentration of 
the vasoactive factor in the plasma. Direct measurement 
of NO concentration is not feasible in everyday clinical 
practice, and the available techniques are burdened 
with a considerable error. However, it is possible to 
assess the concentration of other substances func-
tionally related to the endothelium [1, 2, 17]. The most 
commonly used markers of endothelial function include: 
Table 1. Trials applying endothelial function assessment
Year Number 
of clinical trials
Number of clinical trials




2016 477 434 75,934
2017 432 399 54,673
2018 369 352 50,095
2019 400 374 49,634
2020 195 183 31,882
Total: 1,873 1,742 262,218
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 — Von Willebrand factor, 
 — Thrombomodulin, 
 — Intercellular adhesive molecule (ICAM-1), 
 — Vascular adhesive molecule (VCAM-1), 
 — Plasminogen inhibitor type 1 (PAI-1), 
 — P-selectin and E-selectin, 
 — Vascular endothelial growth factor (VEGF) [1, 2, 10, 17]. 
Another in-vitro test showing damage to the vascular 
endothelium may be a measurement of the number 
of circulating endothelial cells (CEC) in the blood. 
The increase of CEC correlates with other endothelial 
markers, including von Willebrand factor, E-selectin and 
thrombomodulin [1,2,4-6,10]. 
Invasive in-vivo methods 
Invasive methods of endothelial function assess-
ment are mainly used in scientific research due to 
the significant risk of complications resulting from the 
specificity of endovascular procedures [9, 14]. The 
use of invasive techniques was necessary to establish 
a reference standard for the validation of completely 
safe non-invasive methods. Assessment of coronary re-
sponse to local acetylcholine injection introduced in the 
1990s is a widely accepted method. Vasoconstriction 
caused by endothelial dysfunction is recorded indirectly 
by measuring the coronary flow with an endovascular 
Doppler probe or with thermodilution. The measure of 
the coronary arteries lumen with quantitative angiogra-
phy is an alternative to the coronary flow assessment 
[20]. A positron emission tomography (PET) scanner 
[22] and magnetic resonance imaging (MRI) with phase 
contrast [21] were also used to quantify the hyperaemic 
response to the administration of vasoactive agents. 
Non-invasive in-vivo methods 
Flow-mediated skin fluorescence (FMSF) 
One of the non-invasive methods of endothelial 
function assessment is the measurement of fluores-
cence [23]. The FMSF is based on the fluorescence 
measurement of the reduced form of nicotinamide 
adenine dinucleotide (NADH), emitted by the skin cells 
in the band of 420 to 480 nm (peak emission in the 
range 455–465 nm) in response to excitation by UV 
light in the 300 to 400 nm range (recommended range 
is 345–355 nm). The test consists of three phases: 
recording the baseline intensity of the fluorescence 
(usually 1–2 minutes); occlusion phase (usually 5 min-
utes); registration of the response (decay of the NADH 
fluorescence intensity to the baseline, time — up to 
15 minutes) [23]. FMSF allows determining the tissues 
and vascular bed response during ischaemia, while 
the classic techniques based on FMD are based on 
a vasomotor reactivity examination [24]. 
FMD-based methods
The phenomenon of reactive hyperaemia is the 
methodological foundation for almost all currently 
used non-invasive techniques for endothelial function 
assessment. This group of methods is derived from the 
classic technique based on the use of ultrasound for 
direct visualization of brachial artery dilation, which is 
associated with operator-dependent bias. Therefore, 
intensive research is conducted on the development 
of semi-automatic or fully automatic techniques, i.e., 
techniques that do not require the active participation 
of the operator during the test.
Classic FMD method
The classic FMD method assessing the intensity of 
reactive hyperaemia consists of three phases: measure-
ment of the diameter of a selected artery (e.g., brachial); 
stimulation phase; measurement after stimulation. As 
a stimulation, transient ischaemia caused by tightening 
the sphygmomanometric cuff (by inflating it to pressure 
30 to 50 mmHg higher than the baseline systolic blood 
pressure), is usually applied [9–12,16, 22, 25]. Only 
a few publications have reported the use of intra-arterial 
injection of a vasoactive agent: nitro-glycerine [16], 
acetylcholine or methacholine [9–11, 26]. The relative 
change in vessel diameter is rather small, assuming 
values ranging from a few to several per cent compared 
to the pre-occlusion measurement [14, 16, 25]. 
Reactive hyperaemia peripheral arterial tonometry 
(RH-PAT)
RH-PAT — a modified FMD method is used in the 
EndoPAT device (Itamar Medical Ltd.) [27–30]. This 
method uses finger probes with a two-compartment 
pneumatic cuff. The proximal cuff is pumped up to 
a pressure close to the diastolic blood pressure of the 
patient, and its task is to relieve the arteries walls and 
reduce the volume of venous blood in the area of the 
second phalanx of the examined finger [27]. The distal 
cuff, separately connected to the measurement sys-
tem, is used for the actual measurement by pneumatic 
plethysmography. The method has been extensively 
validated in many publications as a diagnostic and pre-
dictive tool in terms of vascular risk assessment [27–32]. 
Thermal method 
The thermal method used in VENDYS devices (En-
dothelix Inc.) is based on recording the temperature of 
two fingers (e.g., index fingers), with one used as a ref-
erence, and the other stimulated with a classic 5-minute 
occlusion with an automatically pumped cuff [33]. The 
tightening of the cuff causes a decrease in the occluded 
limb’s skin temperature in comparison to the baseline 
temperature recorded before cuff inflation. Based on 
the rate of the temperature decay and with the use of 
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a mathematical model, a zero-reactivity curve (ZRC) is 
determined. The third segment of the temperature curve 
recorded after the restoration of perfusion refers to the 
ZRC line and normalized to the reference record from 
the unoccluded (reference) limb. Based on the record 
from the third phase of measurement, a curve of the 
hyperaemic response is drawn [33]. The peak tem-
perature, defined as the maximum point of this curve, 
represents the Vascular Reactivity Index (VRI) [33, 34]. 
Enclosed-zone FMD (EZ-FMD) method 
This method is based on the oscillometric blood 
pressure measurement, where the cuff inflation and 
deflation cycle is repeated six times: at the beginning of 
the measurement (once) to determine the patient’s max-
imum pulse amplitude and five times after a 5-minute of 
a total occlusion. The EZ-FMD coefficient is calculated 
from the formula based on the maximum systolic peak 
in the pre-occlusion phase and the highest peak in the 
post-occlusion phase [35, 36]. 
Photoplethysmography method — reactive 
hyperemia peripheral arterial volume (RH-PAV)
Classic pulse oximetry sensors in the form of finger 
clips can also be used to test endothelial function. A LED 
diode operating in the near-infrared region (940 nm) 
is used for the test. The methodology of calculating 
the result is analogous to that of the RH-PAT index: 
the average amplitudes are calculated from two signal 
intervals recorded: 40 s before occlusion and 40 s after 
cuff deflation. The results are normalized to the oppo-
site non-occluded limb. The authors of the described 
technique called it RH-PAV [37]. 
Impedance plethysmography method
Impedance plethysmography uses changes in the 
electrical impedance of tissues caused by pulsatile 
blood flow. For reactive hyperaemia studies, local 
injection of acetylcholine or methacholine directly into 
one of the forearm arteries was used [21]. 
Laser speckle contrast imaging (LSCI) method 
LSCI is based on the analysis of speckle pattern 
images, formed when illuminating the patient’s skin 
surface with laser light. LSCI allows for two-dimensional 
visualization of peripheral perfusion in the form of a co-
lour map. This method was used to acquire images of 
perfusion changes occurring under the influence of 
acetylcholine and in response to classical stimulation 
with temporary artery occlusion [38, 39]. 
Laser Doppler flowmetry (LDF) method
LDF is used to assess peripheral microcirculation, 
including the measurement of reactive hyperaemia. 
With regard to vascular endothelial studies, the LDF 
method is used to assess reactive hyperaemia in the 
vascular bed of cutaneous vessels. Laser flow meters 
are well suited for recording the early component of the 
hyperaemic response associated with rapid dilation of 
resistance-type vessels (skin arterioles) [41, 42]. 
Pulse velocity wave (PVW) measurement method
This method is based on the measurement of the 
delay of the peak of the peripheral pulse wave, usually 
in relation to the QRS complex in a simultaneously re-
corded ECG — the greater the stiffness of the vessels, 
the faster the pulse wave propagation is observed [43]. 
The delay is calculated from measurements taken 
at two different points of the body, such as the carotid 
and femoral arteries. This technique can also be used 
for endothelial studies [44]. Depending on the adopted 
pulse wave recording points, it is possible not only to 
study the central arterial stiffness but also the peripheral 
regardless of the condition of the aorta. The stiffness of 
the arterial wall depends on the vessel ultrastructure, 
blood pressure and tone of the vascular muscle layer, 
all varying with age. The use of pulse wave velocity 
measurement in endothelial studies is based on the 
assumption that the administration of vasodilators to the 
patient allows the extraction of the last of these compo-
nents. Available studies showed a negative correlation 
between PWV values and endothelial function [43, 44].
Pulse wave analysis (PWA) method
PWA is based on the mathematical decomposition 
of the pulse waveform recorded on the peripheral (usu-
ally radial) artery. Based on the relation of the timing 
and the amplitude data several parameters reflecting 
different aspects of central haemodynamics are deter-
mined. Similarly to the PWV technique, the pulse wave 
analysis may also be supported by pharmacological 
stimulation to determine the range of vascular endo-
thelium response to the administration of vasoactive 
agents [44, 45].
Summary
Endothelial dysfunction playing a pivotal role in the 
pathophysiology of several civilization diseases can 
be detected at the asymptomatic stage. Therefore, 
a non-invasive assessment of endothelial function can 
be applied for early screening in people at increased 
cardiovascular risk. Moreover, endothelial function 
assessment can be used as a method for evaluation 
of treatment effectiveness, as well as for adherence to 
treatment [46–57]. However, until now these methods 
have usually been used only for research purposes, and 
their potential clinical application should be preceded 
by clinical trials. 
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Recent studies indicate the endothelium as the main 
target of SARS-CoV-2, which often causes thrombotic 
complications [58–60]. Therefore, studies aimed to 
assess the usefulness of testing the endothelial function 
also seem advisable in patients with COVID 19.
Currently, none of the known methods of assessing 
vascular endothelial function is widely used in clinical 
practice. This may be a result of various factors: sci-
entific (lack of standardization in terms of quantitative 
indicators of endothelial function), formal (lack of official 
recommendations for endothelial assessment), financial 
(the best-validated methods and devices are costly, 
which renders it unsustainable to use them in screening 
diagnostics) and technological (high susceptibility of 
many measurement methods to errors). 
Nevertheless, it can be expected that non-invasive 
methods for the early detection of endothelial dysfunc-
tion in screening programs will gradually gain impor-
tance.
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